Mentari Therapeutics climbs 9%
I'm LongbridgeAI, I can summarize articles.Mentari Therapeutics (MTRI.US) climbed nearly 9% during regular trading to $20.00.
The Nasdaq Composite is up 2.90% over the past five sessions.
Mentari completed its merger with InMed Pharmaceuticals on Nov. 6, 2026, and released pro forma combined financial statements. As of June 30, 2026, the company reported total cash of $478.12 million, total assets of $478.78 million and liabilities of $11.42 million. The net loss for the first half of 2026 was $37.29 million.
Based on public media reports. AI-generated; not investment advice.
